Why We're Doubling Down on B2B SaaS in 2026
The macro narrative says software multiples are compressed and growth is slowing. We think that is the wrong frame entirely — here is what we are actually seeing.
We focus on growth-stage B2B software companies with proven product-market fit and a clear path to market leadership. Our typical investment is $15–50M and we take an active, partnership-first approach to every portfolio company.
Learn MoreDeep expertise in B2B SaaS, FinTech, and Healthcare Technology — markets we have invested in for over 15 years.
Series B through growth equity. We look for $5–30M ARR with strong net revenue retention and a scalable go-to-market motion.
Every portfolio company gets dedicated support from our in-house talent, marketing, and finance teams — not just board seats.
We are patient capital. Our average hold is 5–7 years and we have co-invested in follow-on rounds for 80% of our portfolio.
Founded in 2006, Apex Capital Partners has grown from a single $120M fund to one of the most active growth equity platforms in North America.
We believe the best companies are built in partnership — and that the right investor brings more than capital to the table. Our team includes former operators, CFOs, and go-to-market leaders who have scaled companies from Series B to IPO.
We are currently deploying Fund IV, a $900M vehicle focused exclusively on B2B SaaS, FinTech, and Healthcare Technology.
A selection of companies where we've partnered with exceptional founders to build category leaders.
Workflow automation for modern ops teams
Active
Embedded payments infrastructure for vertical SaaS
Exited 2024
Revenue intelligence for enterprise sales teams
Active
Care coordination software for multi-site health systems
Active
Insurance verification infrastructure for B2B contracts
Active
AI-native document intelligence for financial services
Active
The macro narrative says software multiples are compressed and growth is slowing. We think that is the wrong frame entirely — here is what we are actually seeing.
When we led Flowlink's Series B in early 2022, they had $8M ARR and a product that resonated but a go-to-market that needed work. Here is what happened next.
Our LPs ask us regularly how growth equity holds up when public market comps are volatile and exit windows feel unpredictable. Here is the honest answer.